Names & Terms You Will Hear
Plain-language meanings for the terms your care team may use.
| Term | Meaning |
|---|---|
| Statins | The class. Block the liver's HMG-CoA reductase enzyme. |
| HMG-CoA reductase inhibitors | The full drug-class name. Same thing. |
| Atorvastatin (Lipitor) | High-intensity statin. Most commonly prescribed worldwide. |
| Rosuvastatin (Crestor) | High-intensity statin. Best LDL lowering per milligram; often best tolerated. |
| Simvastatin (Zocor) | Moderate-intensity. More drug interactions; dose-capped at 40 mg. |
| Pravastatin (Pravachol) | Moderate-intensity. Often well tolerated; fewer drug interactions. |
| Lovastatin / Pitavastatin | Older or newer options. Less common but useful in select patients. |
| Lipid-lowering drugs | Umbrella term. Includes statins plus ezetimibe, PCSK9i, bempedoic acid, inclisiran. |
What Is Statin Therapy?
- Statins are pills that lower LDL cholesterol by blocking the liver enzyme (HMG-CoA reductase) that makes cholesterol.
- When the liver cannot make as much cholesterol, it pulls more LDL out of your blood by adding more LDL receptors to its surface. LDL goes down. That is the main mechanism.
- Statins also stabilize plaque in your arteries — they make existing plaques less likely to crack open and cause a heart attack. This benefit is separate from LDL lowering.
- High-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) lower LDL by 50% or more.
- Moderate-intensity statins (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, pravastatin 40-80 mg, simvastatin 20-40 mg) lower LDL by 30-49%.
- Statins are the most studied class of medication in cardiology — millions of patients across hundreds of trials.
Why It Matters
- Every 39 mg/dL drop in LDL on a statin lowers your risk of heart attack, stroke, and cardiovascular death by about 22% (CTT meta-analysis of 170,000+ patients).
- For someone who already has heart disease, statins lower the risk of dying from any cause — not just heart-related causes.
- For primary prevention (no heart disease yet), statins lower future heart attack and stroke risk in people whose 10-year risk is at least 7.5%.
- Statins work for almost everyone — men, women, older adults, people with diabetes, and patients of every ethnicity studied.
- The benefit shows up within months and grows over years. Stopping the statin reverses most of the protection within weeks.
Risk Factors
Knowing your personal risks helps your care team take extra precautions.
| Risk Factor | Why It Increases Risk |
|---|---|
| Known heart disease (prior MI, stroke, stent, bypass, peripheral artery disease) | Secondary prevention. High-intensity statin is standard of care. Skipping it raises your risk of another event. |
| LDL cholesterol 190 mg/dL or higher | Likely genetic (familial hypercholesterolemia). Statin recommended at any age regardless of other risk factors. |
| Diabetes, age 40-75 | Diabetes itself counts as a heart-disease risk equivalent. Moderate or high-intensity statin recommended. |
| 10-year ASCVD risk 7.5% or higher | Use the AHA/ACC risk calculator. Above 7.5%, statin benefit usually outweighs risk. |
| Elevated Lp(a) | Genetic risk factor. Statins do not lower Lp(a) but still cut overall ASCVD risk in these patients. |
| Family history of early heart disease | Adds to your calculated risk; sometimes pushes a borderline patient over the threshold. |
| Chronic kidney disease | Increases heart-disease risk. Most statins are safe at lower kidney function — dose adjusted. |
| Smoker, high blood pressure, low HDL | Each one raises your calculated risk. Lifestyle + statin together work best. |
Treatment Options
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
- Pick the right intensity. Known heart disease, LDL 190+, or diabetes age 40-75 with high risk -> high-intensity statin. Other primary prevention -> moderate-intensity.
- Recheck a lipid panel 4-12 weeks after starting or changing the dose. Then yearly.
- Goal: at least 50% LDL drop on high-intensity therapy. If your LDL does not fall that much, we look at adherence, dose, or add-on therapy.
- Add ezetimibe (Zetia) if LDL is still too high on max-tolerated statin. Cheap, generic, well tolerated. Extra 15-25% LDL drop.
- PCSK9 inhibitors (alirocumab, evolocumab) — injectable, every 2-4 weeks. Dropped LDL by ~60% on top of a statin in FOURIER and ODYSSEY. Used for very high-risk patients not at goal.
- Bempedoic acid (Nexletol) — oral, statin-intolerant patients. CLEAR Outcomes 2023 showed it cuts MACE.
- Inclisiran (Leqvio) — small interfering RNA injection. Given twice a year after loading. Cuts LDL by ~50%.
- Take it at night? Only for short-acting statins (simvastatin, lovastatin, pravastatin). Atorvastatin and rosuvastatin work any time of day.
Risks, Benefits, and Alternatives
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
Every choice has trade-offs. Use this table to start the shared decision conversation with your care team.
| Option | Risks | Benefits | Alternatives |
|---|---|---|---|
| High-intensity statin (atorvastatin 40-80 / rosuvastatin 20-40) | Muscle aches in 5-10% (most are nocebo per SAMSON trial); rare rhabdomyolysis (<0.1%); ~9% relative increase in new-onset diabetes; transaminase bumps usually benign. | Largest LDL drop. Strongest evidence for cutting heart attack, stroke, and death. Cheap generics. | Moderate-intensity statin; ezetimibe alone; PCSK9i. |
| Moderate-intensity statin (atorvastatin 10-20, rosuvastatin 5-10, pravastatin 40) | Same side-effect classes but generally milder; sometimes inadequate LDL drop. | Better tolerated. Still cuts events meaningfully. Good for primary prevention or step-up dosing. | High-intensity statin if higher risk; combine with ezetimibe. |
| Statin + ezetimibe | Few added side effects. Rare myopathy when combined. | Extra 15-25% LDL drop without raising statin dose. IMPROVE-IT showed event reduction. | Higher-dose statin alone; PCSK9 inhibitor. |
| PCSK9 inhibitor (alirocumab / evolocumab) | Injection-site reaction; cost and prior-auth burden. | Drops LDL ~60% on top of a statin. Cuts MACE in FOURIER and ODYSSEY. | Inclisiran; bempedoic acid; statin + ezetimibe. |
| Bempedoic acid (Nexletol) | Mild uric-acid rise; small gout risk; tendon issues rare. | Oral option for true statin intolerance. CLEAR Outcomes showed MACE reduction. | Re-challenge a different statin; PCSK9i; inclisiran. |
| No therapy (lifestyle only) when statin is indicated | Continued elevated LDL and inflammation. Ongoing plaque progression. Higher risk of MI/stroke. | No drug side effects. | Reduced-dose statin; alternate-day dosing; non-statin LDL therapy. |
Common Misconceptions
| Myth | Reality |
|---|---|
| "Statins cause dementia." | Multiple meta-analyses and RCTs have shown no link between statins and dementia. The FDA briefly added a warning in 2012 based on case reports but later trials and large cohorts (including JUPITER and PROSPER) refuted it. Some studies even suggest a modest protective trend. |
| "All my aches are from the statin." | The SAMSON trial gave patients statin, placebo, and nothing in random order — and 90% of the side-effect burden was the same on placebo as on statin. Real statin myopathy exists, but it is far less common than people think. |
| "I should take CoQ10 to prevent muscle pain." | Randomized trials have not shown CoQ10 prevents or treats statin-related muscle symptoms. It is not harmful, but it is not proven to help. |
| "Natural is safer — red yeast rice instead of a statin." | Red yeast rice contains monacolin K, which is chemically identical to lovastatin. It is an unregulated statin, often with inconsistent dosing and contamination. You get the side effects without dose control or quality assurance. |
| "My LDL is normal now, so I can stop the statin." | Your LDL is normal because of the statin. Within 4-6 weeks of stopping, your LDL returns to baseline and the plaque-stabilizing benefit fades. Only stop on advice from your cardiologist. |
| "Statins damage the liver." | Mild transaminase bumps occur in 1-2% and almost always self-resolve. Serious liver injury is so rare the FDA removed routine liver-test monitoring in 2012. |
| "Statins cause diabetes, so they cancel out the benefit." | JUPITER showed a ~9% relative rise in new-onset diabetes — almost entirely in people already on the cusp. Even in those patients, the heart-attack and stroke reduction far outweighs the diabetes risk. |
Possible Complications
Knowing what can go wrong helps you spot problems early. Most complications are uncommon, especially with treatment.
| Where / What | What Can Happen |
|---|---|
| Muscle pain (myalgia) | 5-10% of patients report it; most cases are nocebo. True myopathy improves with dose reduction or switching to rosuvastatin or pravastatin. |
| Rhabdomyolysis | Severe muscle breakdown. Very rare (<1 per 10,000 patient-years). Warning signs: dark cola-colored urine, severe muscle weakness. |
| New-onset diabetes | ~9% relative increase, especially in pre-diabetic patients. The cardiovascular benefit still outweighs the risk. |
| Liver enzyme elevation | Transient and almost always benign. Routine monitoring is not required after the initial check. |
| Drug interactions | Simvastatin and lovastatin interact with many drugs (CYP3A4). Atorvastatin and rosuvastatin have fewer issues. Always tell us all your medications. |
| Stopping the statin (your own risk) | LDL rebounds in 4-6 weeks. Plaque-stabilizing benefit fades. Most missed-dose 'side effects' come from stopping abruptly. |
Points to Know
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
If you remember nothing else, remember these key points.
- Statins lower heart attack, stroke, and death — not just a cholesterol number.
- If your first statin causes side effects, we try a different one. Most patients tolerate rosuvastatin or pravastatin better than simvastatin.
- Alternate-day or low-dose statin often works when full dose does not — partial benefit is real benefit.
- If statins truly cannot work, we have ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran — all proven to cut events.
- Side effects you read about online are not the same as side effects you will experience. SAMSON proved it.
- Take it daily. Missed doses give back the protection you worked to build.
When to Call Us — and When to Call 911
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
If you are not sure, call. We would rather hear from you twice than miss a real problem.
- Go to the ED for severe muscle weakness, dark cola-colored urine, or new inability to walk — rare but possible rhabdomyolysis.
- Call 911 for chest pain or stroke symptoms regardless of being on a statin.
- Call our office for muscle aches that interfere with daily activities — we will adjust the dose or switch you.
- Call our office if you start any new medication or supplement — drug interactions matter.
- Call our office if you are pregnant or planning pregnancy — statins are stopped during pregnancy.
- Call our office before stopping the statin on your own, even for a few days.
- Call our office if a new provider tells you to stop the statin without consulting our team.
Office: (727) 943-5200
Trusted Resources
Independent, evidence-based pages we recommend for deeper reading.
- 2018 AHA/ACC Cholesterol Guideline (patient summary) — Plain-language summary of indications and statin intensities.
- CDC — About Cholesterol — Federal patient overview of cholesterol and heart disease.
- AHA — Cholesterol Medications — Patient-facing overview of statins and adjuncts.
- National Lipid Association — Patient Resources — Specialty society with deeper-dive patient materials including statin intolerance.
- FH Foundation — Familial Hypercholesterolemia — For patients with LDL >= 190 or strong family history of early heart disease.
Sources Used to Build This Guide
- 2018 AHA/ACC/Multisociety Cholesterol Guideline [guideline] — Primary guideline framework for statin indications (primary prevention, ASCVD risk thresholds, diabetes, LDL >= 190).
- Cholesterol Treatment Trialists' (CTT) Collaboration meta-analysis [review] — Pooled evidence that each 39 mg/dL LDL reduction lowers MACE by ~22%. Anchors the benefit estimate.
- JUPITER trial (Ridker et al, NEJM 2008) [clinical_trial] — Primary prevention RCT showing rosuvastatin reduces MACE in patients with elevated hs-CRP; also flagged the modest new-onset diabetes signal.
- CLEAR Outcomes — bempedoic acid (Nissen et al, NEJM 2023) [clinical_trial] — Evidence base for bempedoic acid in statin-intolerant patients; informs the intolerance algorithm.
- FOURIER trial — evolocumab (Sabatine et al, NEJM 2017) [clinical_trial] — PCSK9 inhibitor cardiovascular outcomes; supports add-on therapy when LDL goals unmet on max statin.
- ODYSSEY OUTCOMES — alirocumab (Schwartz et al, NEJM 2018) [clinical_trial] — Second PCSK9i outcomes trial; supports use post-ACS in patients not at LDL goal.
- SAMSON trial — statin side effects are mostly nocebo (Wood et al, NEJM 2020) [clinical_trial] — N-of-1 crossover trial showing 90% of statin-side-effect burden persists on placebo. Anchors the misconceptions section.
- Statins and dementia — meta-analyses (Power et al, JAMA Neurol 2015) [review] — Refutes the popular claim that statins cause dementia; no signal across RCTs and large cohorts.
- ORION-10/11 — inclisiran (Ray et al, NEJM 2020) [clinical_trial] — Twice-yearly siRNA LDL therapy; included in intolerance algorithm.
- CDC — Cholesterol and Heart Disease [patient_education] — Plain-language patient overview of cholesterol and cardiovascular risk.
- AHA Patient Education — Cholesterol Medications [patient_education] — Patient-facing overview of statins and adjunctive therapies.
